Buy Crypto Markets Spot FuturesGOLD Earn Event Center

Helus Pharma appoints Dr. Ken Kramer as SVP of medical affairs to advance novel mental health treatments. Company developing NSAs for depression and anxiety withHelus Pharma appoints Dr. Ken Kramer as SVP of medical affairs to advance novel mental health treatments. Company developing NSAs for depression and anxiety with

Helus Pharma Appoints Neuroscience Veteran Dr. Ken Kramer to Lead Medical Affairs

Author: Citybuzz

Source: Citybuzz

2026/04/16 21:15

2 min read

For feedback or concerns regarding this content, please contact us at [email protected]

Helus Pharma has appointed Dr. Ken Kramer as senior vice president of medical affairs, effective immediately. The clinical-stage pharmaceutical company, which develops novel serotonergic agonists designed to activate serotonin pathways believed to promote neuroplasticity, stated that Kramer brings more than 20 years of neuroscience-focused medical affairs leadership to the role. His experience includes previous positions at Bristol Myers Squibb, Karuna Therapeutics and AbbVie.

The company expects Kramer to support the advancement of its pipeline and strengthen engagement with clinical and scientific stakeholders. Helus Pharma is developing proprietary NSAs intended to address unmet needs for people suffering from depression, anxiety, and other mental health conditions. The company’s lead candidate, HLP003, is in Phase 3 clinical development for the adjunctive treatment of major depressive disorder and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration.

Another candidate, HLP004, is in Phase 2 development for generalized anxiety disorder. The company maintains an extensive research portfolio of investigational NSAs and operates in Canada, the United States, the United Kingdom and Ireland. For company updates and more information about Helus Pharma, visit www.helus.com.

The appointment comes as Helus Pharma aims to improve the treatment landscape through the introduction of NSAs that provide durable improvements in mental health. With class-leading data according to the company, these developments represent significant potential in a therapeutic area with substantial patient need. The full press release announcing Kramer’s appointment is available at https://ibn.fm/FdEXH.

Blockchain Registration, Verification & Enhancement provided by NewsRamp™

This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Helus Pharma Appoints Neuroscience Veteran Dr. Ken Kramer to Lead Medical Affairs.

The post Helus Pharma Appoints Neuroscience Veteran Dr. Ken Kramer to Lead Medical Affairs appeared first on citybuzz.

Get 20 USDT in Just 1 Minute

Deposit $100 to unlock $300 in GOLD positions

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

Tags:

#DEX